MedWire News: Adding clopidogrel to aspirin treatment in patients at high vascular risk has no effect on the severity of later stroke, say the CHARISMA investigators. The primary finding of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance) trial was that the addition of clopidogrel to aspirin therapy did not reduce the rate of stroke, myocardial infarction, or vascular death in high-risk patients, relative to aspirin alone.
